Skip to Main Content

Paper Details

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
Cancer Immunol Immunother
85
2019
-specific CD8 T cells, AFP, CD3+, CD4, CD4+-, CD4+PD1+ cell, CD8, CD8+, CTLA4, HCC, HLA-DR, HLA-DR+, ICOS, PBMC, PBMCs, PD, PD-1, PD-1+, PD1+, Patients, T cell, Tremelimumab, alpha fetal protein, anti-CTLA4, hepatocellular carcinoma, intra, intra-tumoral T cells, patients, peripheral blood mononuclear cells, survivin, survivin-specific CD8 T cells, tremelimumab, tumor infiltrating CD3, tumor infiltrating CD3+ T cells, tumors
Author NameAffiliation
David AgdashianCenter for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH)
Milan SandhuCenter for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH)
Drew PrattCenter for Cancer Research (CCR) National Cancer Institute, National Institutes of Health
Bradford J WoodCenter for Interventional Oncology, Radiology and Imaging Sciences and Center for Cancer Research, National Institutes of Health
Tim F GretenCenter for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH)
Tim F Greten
Firouzeh KorangyCenter for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH)
  • 1 - 7

Datasets

Release 1.2